If you have hyperthyroidism and take antithyroid medications, inform your provider so they can ensure your thyroid condition is well-controlled before starting GLP-1 therapy
In 1973, John Brown discovered the glucose-dependent insulinotropic polypeptide (GIP) employing peptide purification and protein sequencing, it was shown to have an incretin effect, increasing Insulin release triggered by glucose intake after oral administration [11]
Being overweight or obese may increase the risk of developing conditions such as: Type 2 diabetes High blood pressure High cholesterol Fatty liver disease Sleep apnoea Heart disease Joint problems Certain cancers For many individuals, losing weight through diet and exercise alone can be extremely difficult, especially when the body naturally tries to regain lost weight over time
Recent updates on GLP-1 agonists: current advancements & challenges
See Whether You'd Get Compounded or Branded Medication Prescription medication available only after consultation and approval by a licensed healthcare provider, if clinically appropriate
